Aim 3. Prognostic value of immune signatures
Based on the information generated in the immune profiling (Aim 2), we intend to generate an immune signature for each clinical group. We expect that patients with a better response to treatment will have a different pattern of expression of certain genes related to immune response, compared to those with an early relapse or a histological transformation to an aggressive lymphoma.
We expect that these immune signatures may be implemented into clinical practice to anticipate prognosis, to tailor treatment of patients at higher risk of early relapse or histological transformation.